Clinical trials: Non-hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma…
- Conditions
- B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04594642
- Testing
- AZD0486 IV
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Lymphoma, B-Cell
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
A phase 2 open label study to evaluate safety and activity of Rituximab(HLX01) in combination with Pegylated interferon α-2b in patients with newly diagnosed advanced indolent B-cell lymphoma.
- Trial name
- RIPPLE (NCT04246359)
- Testing
- Rituximab Biosimilar, Pegylated Interferon α-2b
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Huiqiang Huang
B-cell Lymphoma, Indolent B-cell Lymphoma
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
The purpose of this clinical trial is to see if increased doses of rituximab are safe and effective for the initial treatment of indolent B-cell lymphomas.
- Trial name
- NCT00895661
- Testing
- rituximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Non-hodgkin Lymphoma,B Cell
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCCN guidelines for B cell lymphoma suggest that patients with relapsed/refractory aggressive NHL who are candidate for high-dose therapy should receive combination of cytotoxic chemotherapies as 2nd line treatment.
- Trial name
- NCT04094142
- Testing
- Acalabrutinib
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Seoul National University Hospital
Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma
To determine if MDX-1411 is safe for the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.
- Trial name
- MDX1411-02 (NCT00730652)
- Testing
- MDX-1411
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloproliferative Disorders, Leukemia
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT01137643
- Testing
- biologic sample preservation procedure, cytology specimen collection procedure
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma
Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD22:TCRz:4-1BB chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating recurrent patients with refractory or resistant lymphoma to…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Stage III/IV Adult Diffuse Large Cell Lymphoma
- Trial name
- MendCART (NCT02721407)
- Testing
- Retroviral vector-transduced autologous T cells to express CD22-specific CARs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
Lymphoma
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00896519
- Testing
- rituximab, sargramostim, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- French Innovative Leukemia Organisation
B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
This is a study to evaluate the safety of idelalisib as post-transplantation maintenance in patients with B cell hematologic malignancies undergoing a allogeneic hematopoietic stem cell transplant (HSCT).
- Conditions
- B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT03151057
- Testing
- Idelalisib 100 MG
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Follicular Lymphoma
Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression
The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.
- Trial name
- NCT03525665
- Testing
- Metabolic activity measured by FDG-PET
- Where
- 27 sites in Italy
- Volunteers
- 175 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
The goal of this clinical research study is to learn if chemotherapy given with rituximab, followed by Ibritumomab tiuxetan (Zevalin), and then followed by rituximab can help to control lymphoma.
- Trial name
- NCT00290511
- Testing
- Fludarabine, Mitoxantrone, Rituximab
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
T-cell Lymphoma, NK-Cell Lymphoma
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
The designed study follows up on the previous one by the international T-cell project (Bellei et al,, 2012) and its purpose is to verify whether a prospective collection of data would permit access to more accurate information…
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Lymphoma Adults
- Trial name
- Tcell-Brazil (NCT03207789)
- Volunteers
- 500 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Lymphoma, Non-Hodgkin
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade…
- Trial name
- NCT00933335
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)
Long-term Study to Evaluate Safety and Persistence of GF-CART01
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL), Primary Mediastinal Large B-Cell Lymphoma, High Grade B Cell Lymphoma
- Trial name
- NCT06985576
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia
Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma Parents
This is a study protocol to determine whether it is feasible to support parents of children with blood cancers by providing information over an online learning platform. This study will be conducted in Malaysia.
- Conditions
- Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Pediatric Non-Hodgkin Lymphoma, Pediatric Hodgkin Lymphoma
- Trial name
- eHOPE (NCT05455268)
- Testing
- eHOPE, Usual care
- Where
- 2 sites in Malaysia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
The goal of this project is to conduct a pilot randomized clinical trial (RCT) to evaluate the feasibility of a brief, behavioral intervention to improve recovery following hematopoietic stem cell transplantation (HSCT).
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Lymphoid Leukemia
- Trial name
- NCT02955043
- Testing
- Behavioral techniques
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Wisconsin, Madison
Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
- Trial name
- NCT07341191
- Testing
- Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Canadian Cancer Trials Group
Anaplastic Large Cell Lymphoma
BV-CHP Real-life and Biological Evidences in Patients With sALCL
Systemic Anaplastic Large Cell Lymphomas (sALCL) are rare lymphomas for which the cooperation in the collection of biological and clinical data is necessary to improve knowledge on the disease.
- Trial name
- FIL_BREAL (NCT07467317)
- Where
- 19 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.